Aurobindo Pharma’s shares were trading in the red after the company’s subsidiary, APL Healthcare Limited, on 20 September received a ‘Form 483’ with one observation from the USFDA (United States Food and Drug Administration) for its Unit IV plant in Tirupati District, Andhra Pradesh.

The USFDA conducted an inspection from 13-19 September 2023.

The company said that the ‘Form 483’ that was issued with one observation is procedural in nature.

‘Form 483’ is issued by the USFDA when they find a lapse during its inspection of a facility and are guided to take corrective action plans to rectify the issues.

The company said that it would respond within the stipulated timeline and work closely with the USFDA to close the observation.

At 3:22 pm, the shares of Aurobindo Pharma were trading at Rs 890.60 or 0.45% below its previous close on NSE.